Medication Regimens for Managing Acute Asthma

Maselli, Diego J.; Peters, Jay I.

doi:10.4187/respcare.05953

Cited by 21 publications

(15 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MgSO 4 is regularly used in clinical practice. The established indications of MgSO 4 include pre-eclampsia/eclampsia, arrhythmia, and asthma [12,13,14,15]. Although the present study and previous clinical and laboratory studies [21,22,23,24] have indicated that MgSO 4 may exert certain beneficial effects against pulmonary hypertension, evidence that conclusively supports the clinical use of MgSO 4 against pulmonary hypertension is not currently available [34].…”

Section: Discussionmentioning

confidence: 67%

See 1 more Smart Citation

Magnesium Sulfate Mitigates the Progression of Monocrotaline Pulmonary Hypertension in Rats

Chang

Shih

Huang

et al. 2019

IJMS

View full text Add to dashboard Cite

We investigated whether magnesium sulfate (MgSO4) mitigated pulmonary hypertension progression in rats. Pulmonary hypertension was induced by a single intraperitoneal injection of monocrotaline (60 mg/kg). MgSO4 (100 mg/kg) was intraperitoneally administered daily for 3 weeks, from the seventh day after monocrotaline injection. Adult male rats were randomized into monocrotaline (MCT) or monocrotaline plus MgSO4 (MM) groups (n = 15 per group); control groups were maintained simultaneously. For analysis, surviving rats were euthanized on the 28th day after receiving monocrotaline. The survival rate was higher in the MM group than in the MCT group (100% versus 73.3%, p = 0.043). Levels of pulmonary artery wall thickening, α-smooth muscle actin upregulation, right ventricular systolic pressure increase, and right ventricular hypertrophy were lower in the MM group than in the MCT group (all p < 0.05). Levels of lipid peroxidation, mitochondrial injury, inflammasomes and cytokine upregulation, and apoptosis in the lungs and right ventricle were lower in the MM group than in the MCT group (all p < 0.05). Notably, the mitigation effects of MgSO4 on pulmonary artery wall thickening and right ventricular hypertrophy were counteracted by exogenous calcium chloride. In conclusion, MgSO4 mitigates pulmonary hypertension progression, possibly by antagonizing calcium.

show abstract

Section: Discussionmentioning

confidence: 67%

“…Magnesium sulfate (MgSO 4 ) is a natural calcium antagonist [12]. MgSO 4 is used clinically for the treatment of pre-eclampsia/eclampsia, arrhythmia, and asthma [13,14,15,16]. Notably, MgSO 4 is a vasodilator [12].…”

Section: Introductionmentioning

confidence: 99%

Magnesium Sulfate Mitigates the Progression of Monocrotaline Pulmonary Hypertension in Rats

Chang

Shih

Huang

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Moreover, the existing evidence does not provide support for the administration of helium-oxygen mixtures to all emergency department patients with asthma flare-up, with some evidence of certain beneficial effects in patients with more severe obstruction [114]. Very limited and sometimes anecdotic data are present for general anesthesia drugs, or propofol and ketamine [115]. Finally, the recent ERS document on NIV, given the uncertainty of evidence, was unable to offer a recommendation of the use of NIV for acute respiratory failure due to asthma [116].…”

Section: Acute Settingsmentioning

confidence: 99%

The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians

Scichilone

Barnes

Battaglia

et al. 2020

JCM

View full text Add to dashboard Cite

Severe asthma is an important topic in respiratory diseases, due to its high impact on morbidity and mortality as well as on health-care resources. The many challenges that still exist in the management of the most difficult-to-treat forms of the disease, and the acknowledgement of the existence of unexplored areas in the pathophysiological mechanisms and the therapeutic targets represent an opportunity to gather experts in the field with the immediate goals to summarize current understanding about the natural history of severe asthma and to identify gaps in knowledge and research opportunities, with the aim to contribute to improved medical care and health outcomes. This article is a consensus document from the “International Course on Severe Asthma” that took place in Palermo, Italy, on May 10–11, 2019. Emerging topics in severe asthma were addressed and discussed among experts, with special focus on patient’s needs and research opportunities, with the aim to highlight the unanswered questions in the diagnostic process and therapeutic approach.

show abstract

“…3 BA at remission (BA-R) is the absence of asthma symptoms for a period of time, 4 while BA at exacerbation (BA-E) is a progressive increase in asthma symptoms. 5 In recent years, the incidence and mortality rate of BA is on the rise due to the deterioration of environmental pollution, which adversely impacts the health condition and the quality of life of BA patients. 6,7 Therefore, seeking novel biomarkers for BA diagnosis and treatment is critical for BA patients.…”

Section: Introductionmentioning

confidence: 99%

The lncRNA PVT1/miR-423-5p axis is positively correlated with the severity of bronchial asthma

Qiu

Zhang

Liu

et al. 2022

aei

View full text Add to dashboard Cite

Bronchial asthma (BA) is a serious problem affecting the quality of life of patients. Long non-coding RNAs (lncRNAs) are involved in BA. This study set out to investigate expressions of PVT1/miR-423-5p in the serum of BA patients and its clinical value on BA diagnosis and evaluation. This study included the same number (N = 100) of patients with BA at remission (BA-R), BA at exacerbation (BA-E), and healthy controls. PVT1 level was increased in BA-R and BA-E patients, and PVT1 level was higher in BA-E patients than BA-R patients. miR-141-3p targeted PVT1. miR-423-5p was downregulated in the serum of BA patients and was negatively correlated with PVT1. Area under ROC curve of PVT1/miR-423-5p axis on BA-R patients was 0.837 with sensitivity 0.74, specificity 0.84, while that of BA-E was 0.974 with sensitivity 0.87 and specificity 0.95. PVT1/miR-423-5p axis was negatively correlated with FEV1/FVC, FEV1% pred, and IL-10, and positively correlated with IgE, TNF-α, and IL-6. PVT1 and PVT1/miR-423-5p axis were associated with increased severity while miR-423-5p axis was negatively associated with BA severity. In conclusion, increased levels of PVT1/miR-423-5p had higher diagnostic efficiency on BA patients, especially patients with acute exacerbation.

show abstract

Medication Regimens for Managing Acute Asthma

Cited by 21 publications

References 71 publications

Magnesium Sulfate Mitigates the Progression of Monocrotaline Pulmonary Hypertension in Rats

Magnesium Sulfate Mitigates the Progression of Monocrotaline Pulmonary Hypertension in Rats

The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians

The lncRNA PVT1/miR-423-5p axis is positively correlated with the severity of bronchial asthma

Contact Info

Product

Resources

About